Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

Cancer Immunology, Immunotherapy : CII
Zahra MadjdIan Spendlove

Abstract

CD46 or membrane cofactor protein (MCP) is a complement regulatory protein that has been identified on all nucleated cells and which protects them from attack by autologous complement. Breast carcinomas are reported to consistently express CD46. Our previous immunohistochemical study showed that in breast carcinomas, loss of CD59 and CD55 correlated with poor survival. This study aimed to investigate the prognostic significance of CD46 on breast tumours using a rabbit polyclonal anti-CD46 antibody with a standard immunohistochemistry method. A total of 510 breast tissues from patients with primary operable breast cancer diagnosed between 1987 and 1992 had previously been included in tissue microarrays. They included patients 70 years of age or less (mean = 54 years) with a long-term follow-up (median = 82 months). Immunohistochemical study revealed that 507/510 (99.4%) of breast tumours expressed CD46. Strong immunoreactivity was exhibited by 136/510 (27%) tumours, while moderate and weak staining was observed in 43% and 29% of tumours, respectively. Intensity of CD46 expression was significantly associated with tumour grade (p < 0.05), histological type of tumour (p < 0.001) and tumour recurrence (p < 0.05). There was no corre...Continue Reading

References

Jan 1, 1992·Breast Cancer Research and Treatment·M H GaleaI O Ellis
Aug 1, 1989·The Journal of Clinical Investigation·T McNearneyJ P Atkinson
Aug 15, 1989·Biochemical and Biophysical Research Communications·H OkadaJ Kondo
Oct 1, 1987·British Journal of Cancer·J H ToddJ L Haybittle
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·J L ColeJ P Atkinson
Mar 1, 1982·British Journal of Cancer·J L HaybittleK Griffiths
Jan 1, 1996·Advances in Immunology·M K LiszewskiJ P Atkinson
Sep 1, 1996·The Journal of Experimental Medicine·J HamannR A van Lier
Jul 14, 1998·Nature Medicine·J KononenO P Kallioniemi
Nov 10, 1998·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·L ThorsteinssonP M Johnson
Jul 17, 1999·Immunopharmacology·A M Rosengard, J M Ahearn
Oct 26, 1999·Journal of Gastroenterology and Hepatology·F IwataM Itoh
Jan 5, 2001·British Journal of Cancer·L LiL G Durrant
Dec 6, 2001·The American Journal of Pathology·J TorhorstG Sauter
Aug 5, 2003·The Journal of Pathology·Z MadjdL G Durrant
Jan 9, 2004·International Journal of Cancer. Journal International Du Cancer·Neil K RushmereRobert I Nicholson
Apr 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zahra MadjdSarah E Pinder

❮ Previous
Next ❯

Citations

May 24, 2006·Human Gene Therapy·Ilya V UlasovMaciej S Lesniak
Apr 28, 2006·Breast Cancer Research and Treatment·Cari J McDonaldEvanthia Galanis
Feb 18, 2006·Cancer Immunology, Immunotherapy : CII·Ian SpendloveLindy G Durrant
Nov 19, 2013·FEBS Letters·Darrick Carter, André Lieber
Aug 10, 2010·The Journal of Surgical Research·Krista PenningtonJ Michael Mathis
May 19, 2005·International Journal of Cancer. Journal International Du Cancer·Zahra MadjdLindy G Durrant
Jul 20, 2010·Virology·Dan J GustafssonYa-Fang Mei
Oct 27, 2016·Immunological Reviews·Pedro BerraondoRuben Pio
Feb 27, 2010·Environmental Technology·Tine DaelsStijn W H Van Hulle
May 28, 2011·Applied Immunohistochemistry & Molecular Morphology : AIMM·Adam MaciejczykPaweł Surowiak
Sep 12, 2018·International Journal of Molecular Sciences·Manh-Hung DoChaeyong Jung
Apr 30, 2019·Frontiers in Immunology·Ruben PioJohn D Lambris

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.